Statistical analysis of clinical and laboratory data (WP5)

  • Workpackage leader
  • Objectives of the Workpackage
    • To characterise changes over time of tissue damage biomarkers in GVHD patients following Treg-based therapies.
    • To investigate the associations between time-dependent tissue damage biomarkers and clinical data.
    • To identify both clinical and biological predictors of response to therapy (i.e. complete response, partial response, non-responders, progressive disease)

About the clinical trial

The TREGeneration partners

Search
Home
Menu
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

Paul Ehrlich Institute approves cGVHD Trial Read more

Social Media

LinkedIn TREGeneration